BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will participate in the following upcoming investor conferences:   On May 8, Mark Hirschhorn, chief financial officer and chief operating officer, will participate in one-on-one meetings at the Needham & Co. Virtual Technology and Services Conference held virtually. On June 24, Hirschhorn will participate in the Truist Securities Healthcare Dis ...

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in digital care, will report first quarter 2025 operating results after stock market trading hours on Thursday, May 1 2025. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting ...

Company Announcement - Amwell granted 220,844 restricted stock units (RSUs) to Dan Zamansky as an inducement for his employment as chief product and technology officer [1] - The RSUs will vest 25% on the six-month anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over four years [1] - If Zamansky's employment is terminated without cause or for good reason, a portion of the RSUs will vest based on the time he would have remained employed [1] Compensation Committee Approval - The RSU grant was approved by Amwell's Compensation Committee under the Inducement Plan and in accordance with NYSE's Listed Company Manual Rule 303A.08 [2] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to affordable and effective care [3] - The platform supports various clinical programs and aims to deliver integrated, future-ready solutions for millions of patients [3] - Amwell has been serving major healthcare organizations in the U.S. and globally for nearly two decades [3]

Amazon veteran Dan Zamansky joins company’s executive teamBOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leader in technology-enabled care, announced Dan Zamansky, an industry leader in innovation and technology, as the company’s new chief product and technology officer, effective today. Zamansky will lead the company's product and R&D organizations. He will focus on the comprehensive technology-enabled care platform Amwell offers payers and health systems to provide individuals with bet ...

Core Points - Amwell granted RSUs covering 16,737 shares of its Class A common stock to four new employees as an inducement for their employment [1][2] - The RSUs will vest 25% on the first anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over three years [1] - The grants were approved by the Compensation Committee under Amwell's Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08 [2] Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to affordable and effective care [3] - The platform supports various clinical programs and offers integrated solutions for patients seeking care online, operating at a large scale to serve millions [3] - Amwell has been serving major healthcare organizations in the U.S. and globally for nearly two decades [3]

Company Overview - Amwell is a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, offering payers and health systems a unified care platform [2] - The platform enhances patient access to convenient, affordable, and effective care, integrating various clinical programs [2] - Amwell has been operational for almost two decades, serving major healthcare organizations in the U.S. and globally [2] Upcoming Events - Amwell will participate in the TD Cowen 24th Annual Health Care conference in Boston on March 4, 2025 [1] - Ido Schoenberg, M.D., the chairman and CEO of Amwell, will engage in a fireside chat at 9:10 a.m. ET, with an audio webcast available for investors [1]

American Well Corporation (NYSE:AMWL) Q4 2024 Earnings Conference Call February 12, 2025 5:00 PM ET Company Participants Sue Dooley - Head of Investor Relations Ido Schoenberg - Chairman & Chief Executive Officer Mark Hirschhorn - Chief Financial Officer Conference Call Participants Craig Hettenbach - Morgan Stanley Stan Berenshteyn - Wells Fargo Securities Jailendra Singh - Truist Securities Eric Percher - Nephron Research Charles Rhyee - TD Cowen Matt Shea - Needham & Company Kevin Caliendo - UBS David La ...

American Well Corporation (AMWL) reported $71.01 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 0.5%. EPS of -$2.77 for the same period compares to -$3.40 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $66.57 million, representing a surprise of +6.67%. The company delivered an EPS surprise of +1.77%, with the consensus EPS estimate being -$2.82.While investors closely watch year-over-year changes in headline numbers -- revenue a ...

Digital Care Platform and Market - As of December 31, 2024, Amwell powers digital care programs for approximately 50 health plans covering over 80 million lives and has facilitated more than 33.1 million virtual care visits since inception, including 5.9 million in 2024[19]. - The total addressable market (TAM) for Amwell's hybrid care platform is estimated at approximately $31 billion, projected to grow to roughly $50 billion over the next four years[35]. - The TAM for virtual clinical services offered through Amwell's platform is part of a growing $40 billion virtual care market opportunity[36]. - Amwell's enterprise platform enables a member-centric hybrid care experience, integrating various care modalities including primary, urgent, and behavioral health[21]. - The company has identified over 290 million lives enrolled in insurance plans as potential subscribers to its platform, along with 930 health systems that could benefit from its services[37]. Platform Adoption and User Experience - In Q4 2024, 67% of visits were conducted on the Amwell Converge™ platform, up from 52% in Q4 2023, indicating a significant increase in platform adoption[26]. - The Amwell Converge platform received a patient satisfaction rating of over 90% for the full-year period ended December 31, 2024, reflecting high user approval[31]. - Amwell's platform is designed to be flexible and scalable, allowing clients to expand their hybrid care delivery as their needs evolve[43]. - Amwell's platform enables seamless integration of third-party and first-party applications, enhancing client capabilities and patient care delivery[44]. Services and Technology Integration - The company offers a full suite of value-added services, including licensed medical staffing through AMG, to support clients' hybrid care strategies[34]. - The company is focusing on creating a digital formulary to provide high-quality vetted apps and services, responding to client demand for fewer technology partners[45]. - Amwell's platform integrates with EHR systems like Epic and Oracle Health, streamlining administrative functions and improving workflows for clients[47]. - The platform is built on FHIR standards, ensuring interoperability with healthcare systems and enabling third-party developers to enhance its capabilities[70]. Financial Performance and Client Base - In 2024, the company incurred net losses of $212.6 million, $679.2 million, and $272.1 million for the years ended December 31, 2024, 2023, and 2022, respectively, with an accumulated deficit of $1,965.9 million as of December 31, 2024[153]. - The largest client, Elevance Health, accounted for 27% of total revenue in 2024, with the top ten clients contributing 58% of total revenue[154]. - The company generates most of its revenue from clients purchasing access to its enterprise platform, with contracts typically having initial terms of three years[169]. Research, Development, and Innovation - Amwell's research and development team focuses on enhancing usability, functionality, and performance of products, with development offices in Israel and Colombia[81]. - The company has invested significant resources in research and development to enhance its existing solutions and introduce new products[174]. - The company continues to focus on expanding its services and investing in research and development to increase its client and patient base[153]. Environmental, Social, and Governance (ESG) Initiatives - The company has made significant progress on its ESG goals, reporting on advancements in its 2024 Corporate Responsibility Report[121]. - The company is committed to lowering carbon emissions and the overall environmental impact of healthcare delivery[124]. - The ESG strategy is overseen by a task force comprising experts from various departments and is connected to strategic business initiatives[123]. - The company is focused on three pillars in its ESG approach: People, Products, and Operations[125]. Regulatory and Compliance Challenges - The company is subject to various international privacy and data protection laws, including GDPR and UK GDPR, which impose stringent requirements[112]. - The company must comply with state and federal health information privacy laws, including HIPAA, which establishes standards for the protection of personal health information[103]. - Violations of GDPR or UK GDPR could result in significant regulatory penalties and reputational damage for the company[118]. Operational and Market Risks - The company faces competition from various players, including Teladoc and Amazon, which could lead to pricing pressures and impact sales[162]. - Economic uncertainties could disproportionately affect demand for the company's solutions, impacting revenue and financial results[194]. - The sales cycle for the company's solutions can be long and unpredictable, leading to fluctuations in results of operations[192]. - The company incurs significant upfront costs in client relationships, which must be recovered over time through successful client retention[191]. Workforce and Talent Management - As of December 31, 2024, the company had 877 full-time employees, with 83% based in the United States and women representing nearly 49% of the global workforce[129][130]. - The company has implemented a competitive intern program and partnerships with universities to build a strong talent pipeline[130]. - The company’s total rewards framework includes competitive compensation packages linked to individual and company performance, as well as a robust suite of benefits[132]. Technical and Infrastructure Challenges - The company relies on two geographically dispersed data centers to serve U.S. clients, which may expose it to risks if agreements with data center operators cannot be renewed on commercially reasonable terms[200]. - Security breaches or failures in the company's or third-party vendors' systems could lead to unauthorized access to sensitive data, harming reputation and incurring significant liabilities[207]. - The company must continuously update its information systems to protect against vulnerabilities, with increased risks due to the ongoing conflict in Russia and Ukraine[211].

Exhibit 99.1 AMWELL® ANNOUNCES RESULTS FOR FOURTH QUARTER AND FULL YEAR 2024 BOSTON, Feb. 12, 2025 –Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. "During 2024, we advanced our business in ways that put us much closer to unlocking the value of Amwell and advancing our mission to modernize healthcare with our unified platform," said Ido Schoenberg, MD, ch ...